Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible TuberculosisPayam Nahid, Andrew Vernon, Susan E. Dorman et al.|Clinical Infectious Diseases|2016Cited by 1.5k
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy studySusan E. Dorman, Samuel G. Schumacher, David Alland et al.|The Lancet Infectious Diseases|2017Cited by 688
Four-Month Rifapentine Regimens with or without Moxifloxacin for TuberculosisSusan E. Dorman, Richard E. Chaisson, Payam Nahid et al.|New England Journal of Medicine|2021Cited by 548
Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible TuberculosisPayam Nahid, Andrew Vernon, Susan E. Dorman et al.|Clinical Infectious Diseases|2016Cited by 321
Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary TuberculosisSusan E. Dorman, Richard E. Chaisson, John L. Johnson et al.|American Journal of Respiratory and Critical Care Medicine|2009Cited by 266